CN110267645A - 用于治疗干眼病的眼用组合物 - Google Patents
用于治疗干眼病的眼用组合物 Download PDFInfo
- Publication number
- CN110267645A CN110267645A CN201780079941.0A CN201780079941A CN110267645A CN 110267645 A CN110267645 A CN 110267645A CN 201780079941 A CN201780079941 A CN 201780079941A CN 110267645 A CN110267645 A CN 110267645A
- Authority
- CN
- China
- Prior art keywords
- composition
- cyclosporine
- dry eye
- item
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 559
- 238000011282 treatment Methods 0.000 title claims abstract description 127
- 208000003556 Dry Eye Syndromes Diseases 0.000 title claims description 248
- 206010013774 Dry eye Diseases 0.000 title claims description 135
- 229930182912 cyclosporin Natural products 0.000 claims abstract description 317
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 119
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 374
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 326
- 108010036949 Cyclosporine Proteins 0.000 claims description 324
- 229960001265 ciclosporin Drugs 0.000 claims description 324
- 229930105110 Cyclosporin A Natural products 0.000 claims description 97
- 230000006378 damage Effects 0.000 claims description 79
- 206010013932 dyslexia Diseases 0.000 claims description 63
- 230000000699 topical effect Effects 0.000 claims description 22
- -1 polyethylene Polymers 0.000 claims description 16
- 239000004698 Polyethylene Substances 0.000 claims description 8
- 239000004743 Polypropylene Substances 0.000 claims description 8
- 229920000573 polyethylene Polymers 0.000 claims description 8
- 229920001155 polypropylene Polymers 0.000 claims description 8
- 239000000607 artificial tear Substances 0.000 claims description 7
- 229920001903 high density polyethylene Polymers 0.000 claims description 6
- 239000004700 high-density polyethylene Substances 0.000 claims description 6
- 229920001684 low density polyethylene Polymers 0.000 claims description 4
- 239000004702 low-density polyethylene Substances 0.000 claims description 4
- 239000012815 thermoplastic material Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 177
- 108010036941 Cyclosporins Proteins 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 134
- 238000010186 staining Methods 0.000 description 117
- 239000000243 solution Substances 0.000 description 113
- 230000002354 daily effect Effects 0.000 description 88
- 239000006196 drop Substances 0.000 description 62
- 230000009467 reduction Effects 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 230000002123 temporal effect Effects 0.000 description 26
- 239000000839 emulsion Substances 0.000 description 23
- 230000009471 action Effects 0.000 description 21
- 239000003755 preservative agent Substances 0.000 description 18
- GYDMBTYTWYNRGO-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4-nonafluorononane Chemical compound CCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)F GYDMBTYTWYNRGO-UHFFFAOYSA-N 0.000 description 17
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 16
- 206010047571 Visual impairment Diseases 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 208000029257 vision disease Diseases 0.000 description 13
- 230000004393 visual impairment Effects 0.000 description 13
- 210000004087 cornea Anatomy 0.000 description 12
- KZMRYBLIGYQPPP-UHFFFAOYSA-M 3-[[4-[(2-chlorophenyl)-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]cyclohexa-2,5-dien-1-ylidene]methyl]-n-ethylanilino]methyl]benzenesulfonate Chemical compound C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)Cl)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 KZMRYBLIGYQPPP-UHFFFAOYSA-M 0.000 description 11
- 210000000795 conjunctiva Anatomy 0.000 description 10
- 206010047513 Vision blurred Diseases 0.000 description 8
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 208000028006 Corneal injury Diseases 0.000 description 5
- 208000023715 Ocular surface disease Diseases 0.000 description 5
- 150000001335 aliphatic alkanes Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000011200 topical administration Methods 0.000 description 5
- 206010015946 Eye irritation Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 231100000013 eye irritation Toxicity 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000004489 tear production Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010015958 Eye pain Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000004397 blinking Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003560 epithelium corneal Anatomy 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000001493 Cyclophilins Human genes 0.000 description 2
- 108010068682 Cyclophilins Proteins 0.000 description 2
- NPEONIHYDZZZGH-UHFFFAOYSA-N Cyclosporin T Natural products CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)NC(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O NPEONIHYDZZZGH-UHFFFAOYSA-N 0.000 description 2
- 206010022459 Instillation site pain Diseases 0.000 description 2
- 101100333728 Mus musculus Ercc8 gene Proteins 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000004561 lacrimal apparatus Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 229940053174 restasis Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010719 Conjunctival haemorrhage Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 206010010804 Contact lens intolerance Diseases 0.000 description 1
- 241000179197 Cyclospora Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000000521 Immunophilins Human genes 0.000 description 1
- 108010016648 Immunophilins Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010053459 Secretion discharge Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- PMATZTZNYRCHOR-UHFFFAOYSA-N cyclosporine a Chemical compound CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004175 meibomian gland Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229930001118 polyketide hybrid Natural products 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
- A61J1/067—Flexible ampoules, the contents of which are expelled by squeezing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16206735 | 2016-12-23 | ||
| EP16206735.9 | 2016-12-23 | ||
| EP17165578.0 | 2017-04-07 | ||
| EP17165578 | 2017-04-07 | ||
| PCT/EP2017/083770 WO2018115097A1 (en) | 2016-12-23 | 2017-12-20 | Ophthalmic composition for treatment of dry eye disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110267645A true CN110267645A (zh) | 2019-09-20 |
Family
ID=61002978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780079941.0A Pending CN110267645A (zh) | 2016-12-23 | 2017-12-20 | 用于治疗干眼病的眼用组合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20180360908A1 (enExample) |
| EP (3) | EP3777830B1 (enExample) |
| JP (2) | JP7032404B2 (enExample) |
| KR (1) | KR102288022B1 (enExample) |
| CN (1) | CN110267645A (enExample) |
| AU (1) | AU2017384650B2 (enExample) |
| BR (1) | BR112019012791A2 (enExample) |
| CA (1) | CA3045743C (enExample) |
| DK (1) | DK3399962T3 (enExample) |
| ES (2) | ES2965883T3 (enExample) |
| MX (1) | MX381639B (enExample) |
| PL (1) | PL3399962T3 (enExample) |
| PT (1) | PT3399962T (enExample) |
| WO (1) | WO2018115097A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115066178A (zh) * | 2020-02-07 | 2022-09-16 | 德马利克治疗公司 | 抗寄生虫组合物 |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012023421B1 (pt) | 2010-03-17 | 2021-09-14 | Novaliq Gmbh | Composição farmacêutica para tratamento de aumento de pressão intraocular |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| CA3142049C (en) | 2012-09-12 | 2023-08-29 | Novaliq Gmbh | Semifluorinated alkane compositions |
| CA2997744C (en) | 2012-09-12 | 2019-12-31 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| CA2918419C (en) | 2013-07-23 | 2022-05-03 | Novaliq Gmbh | Stabilized antibody compositions |
| WO2017055454A1 (en) | 2015-09-30 | 2017-04-06 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| DK3356313T3 (da) | 2015-09-30 | 2020-07-20 | Novaliq Gmbh | 2-perfluorhexyloktan til oftalmisk indgivelse |
| JP2019520357A (ja) | 2016-06-23 | 2019-07-18 | ノバリック ゲーエムベーハー | 局所投与方法 |
| WO2018054932A1 (en) | 2016-09-22 | 2018-03-29 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
| CN109906085B (zh) | 2016-09-23 | 2024-03-08 | 诺瓦利克有限责任公司 | 含有环孢素的眼用组合物 |
| PL3612228T3 (pl) | 2017-04-21 | 2024-04-08 | Dermaliq Therapeutics, Inc. | Kompozycje jodu |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| SG11202002640YA (en) | 2017-09-27 | 2020-04-29 | Novaliq Gmbh | Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| CA3091308A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| WO2019206956A1 (en) | 2018-04-27 | 2019-10-31 | Novaliq Gmbh | Ophthalmic compositions comprising tafluprost for the treatment of glaucoma |
| US12472162B2 (en) * | 2018-07-24 | 2025-11-18 | Carefusion 213, Llc | Ready-to-use, terminally sterile packaging for surgical antiseptic and method of use |
| MY206642A (en) * | 2018-10-12 | 2024-12-30 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| US12397039B2 (en) | 2019-02-13 | 2025-08-26 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| US20220226426A1 (en) * | 2019-05-24 | 2022-07-21 | Novaliq Gmbh | Ophthalmic composition for the treatment of ocular allergy |
| AU2020340561A1 (en) * | 2019-09-06 | 2022-03-31 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2335735A1 (en) * | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| US20160243189A1 (en) * | 2012-06-20 | 2016-08-25 | University Of Waterloo | Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013126602A1 (en) * | 2012-02-21 | 2013-08-29 | Massachusetts Eye & Ear Infirmary | Inflammatory eye disorders |
| CA2997744C (en) * | 2012-09-12 | 2019-12-31 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
| KR20150095684A (ko) * | 2012-12-18 | 2015-08-21 | 노파르티스 아게 | 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법 |
| CN106572941B (zh) * | 2014-08-13 | 2020-06-23 | 佛罗里达大学研究基金会股份有限公司 | 从眼药水中去除防腐剂 |
-
2017
- 2017-12-20 ES ES20178792T patent/ES2965883T3/es active Active
- 2017-12-20 WO PCT/EP2017/083770 patent/WO2018115097A1/en not_active Ceased
- 2017-12-20 PL PL17832066T patent/PL3399962T3/pl unknown
- 2017-12-20 ES ES17832066T patent/ES2819005T3/es active Active
- 2017-12-20 BR BR112019012791A patent/BR112019012791A2/pt not_active Application Discontinuation
- 2017-12-20 EP EP20178792.6A patent/EP3777830B1/en active Active
- 2017-12-20 DK DK17832066.9T patent/DK3399962T3/da active
- 2017-12-20 CN CN201780079941.0A patent/CN110267645A/zh active Pending
- 2017-12-20 KR KR1020197021384A patent/KR102288022B1/ko active Active
- 2017-12-20 CA CA3045743A patent/CA3045743C/en active Active
- 2017-12-20 MX MX2019007587A patent/MX381639B/es unknown
- 2017-12-20 JP JP2019533180A patent/JP7032404B2/ja active Active
- 2017-12-20 EP EP23212280.4A patent/EP4374851A3/en active Pending
- 2017-12-20 AU AU2017384650A patent/AU2017384650B2/en active Active
- 2017-12-20 EP EP17832066.9A patent/EP3399962B1/en active Active
- 2017-12-20 PT PT178320669T patent/PT3399962T/pt unknown
-
2018
- 2018-08-22 US US16/109,127 patent/US20180360908A1/en not_active Abandoned
-
2021
- 2021-12-31 JP JP2021215498A patent/JP2022050514A/ja not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2335735A1 (en) * | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| US20160243189A1 (en) * | 2012-06-20 | 2016-08-25 | University Of Waterloo | Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof |
Non-Patent Citations (1)
| Title |
|---|
| GEHLSEN等: "Cyclosporine A using F4H5 as liquid drug carrier is effective in treating experimental dry-eye disease", 《INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115066178A (zh) * | 2020-02-07 | 2022-09-16 | 德马利克治疗公司 | 抗寄生虫组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2965883T3 (es) | 2024-04-17 |
| US20230043641A1 (en) | 2023-02-09 |
| MX381639B (es) | 2025-03-13 |
| PT3399962T (pt) | 2020-09-03 |
| EP3777830A1 (en) | 2021-02-17 |
| PL3399962T3 (pl) | 2021-02-08 |
| EP3399962B1 (en) | 2020-06-10 |
| BR112019012791A2 (pt) | 2019-12-03 |
| AU2017384650A1 (en) | 2019-07-04 |
| MX2019007587A (es) | 2019-12-16 |
| AU2017384650B2 (en) | 2021-02-18 |
| CA3045743C (en) | 2023-08-29 |
| EP3777830B1 (en) | 2023-11-29 |
| EP3399962A1 (en) | 2018-11-14 |
| JP7032404B2 (ja) | 2022-03-08 |
| WO2018115097A9 (en) | 2018-08-23 |
| EP3777830C0 (en) | 2023-11-29 |
| JP2020502197A (ja) | 2020-01-23 |
| US20180360908A1 (en) | 2018-12-20 |
| DK3399962T3 (da) | 2020-09-07 |
| WO2018115097A1 (en) | 2018-06-28 |
| JP2022050514A (ja) | 2022-03-30 |
| ES2819005T3 (es) | 2021-04-14 |
| EP4374851A3 (en) | 2024-08-21 |
| EP4374851A2 (en) | 2024-05-29 |
| KR20190100283A (ko) | 2019-08-28 |
| KR102288022B1 (ko) | 2021-08-10 |
| CA3045743A1 (en) | 2018-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017384650B2 (en) | Ophthalmic composition for treatment of dry eye disease | |
| US12059449B2 (en) | Ophthalmic composition for treatment of dry eye disease | |
| AU2020281641B2 (en) | Ophthalmic composition for the treatment of ocular allergy | |
| US12496326B2 (en) | Ophthalmic composition for treatment of dry eye disease | |
| RU2828769C2 (ru) | Офтальмологические композиции для лечения синдрома сухого глаза | |
| HK40113015A (en) | Ophthalmic composition for treatment of dry eye disease | |
| HK40114301A (en) | Ophthalmic composition for treatment of dry eye disease | |
| HK40000392B (en) | Ophthalmic composition for treatment of dry eye disease | |
| HK40000392A (en) | Ophthalmic composition for treatment of dry eye disease | |
| HK40058504B (en) | Ophthalmic composition for treatment of dry eye disease | |
| HK40058504A (en) | Ophthalmic composition for treatment of dry eye disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |